BRPI0813966A2 - Usos de mdl-1 - Google Patents

Usos de mdl-1

Info

Publication number
BRPI0813966A2
BRPI0813966A2 BRPI0813966-0A2A BRPI0813966A BRPI0813966A2 BR PI0813966 A2 BRPI0813966 A2 BR PI0813966A2 BR PI0813966 A BRPI0813966 A BR PI0813966A BR PI0813966 A2 BRPI0813966 A2 BR PI0813966A2
Authority
BR
Brazil
Prior art keywords
cdm
Prior art date
Application number
BRPI0813966-0A2A
Other languages
English (en)
Inventor
Michael E Bigler
Daniel J Cua
Barbara Joyce-Shaikh
Joseph H Phillips
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0813966A2 publication Critical patent/BRPI0813966A2/pt
Publication of BRPI0813966A8 publication Critical patent/BRPI0813966A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0813966A 2007-06-29 2008-06-24 Usos de mdl-1 BRPI0813966A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94731407P 2007-06-29 2007-06-29
PCT/US2008/068042 WO2009006112A1 (en) 2007-06-29 2008-06-24 Mdl-1 uses

Publications (2)

Publication Number Publication Date
BRPI0813966A2 true BRPI0813966A2 (pt) 2015-01-06
BRPI0813966A8 BRPI0813966A8 (pt) 2016-02-10

Family

ID=39712082

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813966A BRPI0813966A8 (pt) 2007-06-29 2008-06-24 Usos de mdl-1

Country Status (10)

Country Link
US (2) US20100221252A1 (pt)
EP (1) EP2176294B1 (pt)
JP (2) JP5171948B2 (pt)
CN (1) CN101802011A (pt)
AU (1) AU2008270710A1 (pt)
BR (1) BRPI0813966A8 (pt)
CA (1) CA2691618A1 (pt)
ES (1) ES2540854T3 (pt)
WO (1) WO2009006112A1 (pt)
ZA (1) ZA201000393B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
WO2011053630A1 (en) * 2009-10-30 2011-05-05 Schering Corporation Uses of a mammalian cytokine
RU2663123C2 (ru) 2010-11-30 2018-08-01 Чугаи Сейяку Кабусики Кайся Индуцирующий цитотоксичность терапевтический агент
WO2012112528A1 (en) * 2011-02-18 2012-08-23 Merck Sharp & Dohme Corp. Use of mdl-1 antagonists to treat spondylarthropathy
US20140227719A1 (en) * 2011-09-23 2014-08-14 Merck Sharp & Dohme Corp Mdl-1 ligand
AU2012323849B2 (en) * 2011-10-13 2017-04-20 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
CA2853230C (en) 2011-10-31 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
DK2780373T3 (da) 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
BR112016026299A2 (pt) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
KR20180091918A (ko) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
JP7420827B2 (ja) 2019-03-08 2024-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ－３６ｒ抗体製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
WO2005027848A2 (en) * 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
AR059193A1 (es) * 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
CN101986783A (zh) * 2007-04-23 2011-03-16 先灵公司 抗mdl-1抗体

Also Published As

Publication number Publication date
EP2176294B1 (en) 2015-05-20
JP2012233008A (ja) 2012-11-29
WO2009006112A1 (en) 2009-01-08
CN101802011A (zh) 2010-08-11
US20120177647A1 (en) 2012-07-12
JP2010532369A (ja) 2010-10-07
ES2540854T3 (es) 2015-07-14
US20100221252A1 (en) 2010-09-02
CA2691618A1 (en) 2009-01-08
JP5171948B2 (ja) 2013-03-27
EP2176294A1 (en) 2010-04-21
ZA201000393B (en) 2014-03-26
BRPI0813966A8 (pt) 2016-02-10
AU2008270710A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
NO2022048I1 (no) onasemnogene abeparvovec
BRPI0813966A2 (pt) Usos de mdl-1
BRPI0818380A2 (pt) Combinação de herbicida-protetor
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
BRPI0810191A2 (pt) Escova de dentes
BRPI0817935A2 (pt) Derivados de biarila
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0814236A2 (pt) Derivados de quinazolinamida
FI20075517A (fi) Kenkäpuristinhihna
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
FI20075873A (fi) Suotokuristinjärjestely
AT505058A3 (de) Türschliesssystem
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol
BRPI0808029A2 (pt) Derivados de azabicicloalcano de subtipo seletivo
BRPI0811214A2 (pt) Derivados de pirazolona
FR2925545B1 (fr) Nacelle de securite
BRPI0812827A2 (pt) Derivados de macrolactona
BRPI0812816A2 (pt) Derivados de sulfonil-quinolina
FI20075310A0 (fi) Aksiaalivuoinduktiosähkökone

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.